PYXS חוב לטווח קצר של החברה Pyxis Oncology

Pyxis Oncology, Inc. (PYXS) develops oncology treatments by stimulating the body's own immune defenses. This chart of the market price helps assess an asset whose success depends on the safety of new treatment methods and the availability of funding for trials. The indicator stands at 0.01. High research costs and strict regulatory oversight, combined with patent protection, create significant barriers to entry for new players.

This metric is calculated as the sum of all liabilities with a maturity of up to one year. This indicator determines current liquidity and the issuer's ability to service short-term loans. For Pyxis Oncology, Inc. (PYXS), this is a critical marker of available capital for conducting costly clinical trials of anti-cancer drugs. Analyzing total short-term debt allows for an assessment of the risk of funding shortages before the completion of scientific trials. The trend in total short-term debt reveals the real financial stability of the company.